Safety, tolerability, and pharmacokinetics of HRS9432(A) injection in healthy Chinese subjects: a phase-I randomized, double-blind, dose escalation, placebo-controlled study
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00524-24 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Xin Yan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Antifungal Agents, Healthy Volunteers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HSTD | Natural Science Foundation of Hunan Province ().
Abstract (Originalsprache)
HRS9432(A) is a long-acting echinocandin antifungal medication primarily used to treat invasive fungal infections, particularly invasive candidiasis. The safety, tolerability, and pharmacokinetic characteristics of HRS9432(A) injection were investigated in a randomized, double-blind, placebo-controlled, single- and multiple-ascending-dose Phase I study involving 56 healthy adult subjects. Doses ranging from 200 to 1200 mg were administered. Safety was continually monitored, including adverse events, clinical laboratory examinations, vital signs, 12-lead electrocardiograms, and physical examinations, while the pharmacokinetic profile within the body was evaluated. The results indicated that concentrations of HRS9432 peaked immediately after infusion, demonstrating essentially linear pharmacokinetic characteristics within the dosage range of 200–1,200 mg. It exhibited a low clearance rate and an extended half-life, with a clearance of approximately 0.2 L/h, a volume of distribution of around 40 L, and a half-life of approximately 140h following a single dose. The accumulation index for AUC0-τ after multiple doses ranged from 1.41 to 1.75. No severe adverse events occurred during the study, and the severity of all adverse events was mild or moderate. Therefore, the intravenous administration of HRS9432(A) in healthy Chinese adult subjects, either as multiple infusions of 200 to 600 mg (once a week, four doses) or as a single infusion of 900–1,200 mg, demonstrated overall good safety and tolerability. The pharmacokinetic exhibited essentially linear characteristics in the body, supporting a weekly dosing frequency for clinical applications and providing additional options for the treatment or prevention of invasive fungal infections. CLINICAL TRIALS This study is registered with the International Clinical Trials Registry Platform as ChiCTR2300073525 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China.
- Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China.
- Clinical Pharmacology Center, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
ORCID-Profile: Jie Huang, Guoping Yang
Förderung
- HSTD | Natural Science Foundation of Hunan Province ()
Zitieren
APA
Yan, X., Huang, Y., Xie, J., Wu, Q., Yang, S., Yang, X., Chen, H., Huang, J., & Yang, G. (2024). Safety, tolerability, and pharmacokinetics of HRS9432(A) injection in healthy Chinese subjects: a phase-I randomized, double-blind, dose escalation, placebo-controlled study. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00524-24
Vancouver
Yan X, Huang Y, Xie J, Wu Q, Yang S, Yang X, et al. Safety, tolerability, and pharmacokinetics of HRS9432(A) injection in healthy Chinese subjects: a phase-I randomized, double-blind, dose escalation, placebo-controlled study. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00524-24
BibTeX
@article{Yan2024,
author = {Yan, Xin and Huang, Yuanyuan and Xie, Jinlian and Wu, Qian and Yang, Shuang and Yang, Xiaoyan and Chen, Honghui and Huang, Jie and Yang, Guoping},
title = {Safety, tolerability, and pharmacokinetics of HRS9432(A) injection in healthy Chinese subjects: a phase-I randomized, double-blind, dose escalation, placebo-controlled study},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00524-24}
}
EUVIMED